First in Human SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19
Status:
Completed
Trial end date:
2020-07-01
Target enrollment:
Participant gender:
Summary
This is a phase 1 study in healthy subjects to evaluate the safety, tolerability and
pharmacokinetics of single (Part A and B) and multiple (Part B) doses of inhaled TD-0903.